Both drugs mitigated PM<sub>2.5</sub>-induced systolic blood pressure increases and partially prevented endothelial dysfunction, as reflected by a mixed effect on endothelial nitric oxide synthase phosphorylation. The gene discussed is NOS3; the disease is endothelial dysfunction.